| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xuan Li, Xiaoyun Guo, Xiaoduo Fan, Tienan Feng, Chuanyue Wang, Zhijian Yao, Xiufeng Xu, Zhiyu Chen, Huiling Wang, Shoufu Xie, Jiangjiang He, Kaiming Zhuo, Qiong Xiang, Haixin Cen, Jinhong Wang, Robert C Smith, Hua Jin, Matcheri S Keshavan, Stephen R Marder, John M Davis, Kaida Jiang, Yifeng Xu, Dengtang Li. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophrenia research. vol 230. 2021-07-02. PMID:33279374. |
it will also provide evidence for the efficacy and safety of using clozapine in the early phase of schizophrenia treatment by comparing with other sgas. |
2021-07-02 |
2023-08-13 |
human |
| Satish Suhas, Vijay Kumar, Ganesan Venkatasubramania. Therapeutic drug monitoring of clozapine in Indian patients with schizophrenia - Authors response. Schizophrenia research. vol 229. 2021-07-02. PMID:33609987. |
therapeutic drug monitoring of clozapine in indian patients with schizophrenia - authors response. |
2021-07-02 |
2023-08-13 |
Not clear |
| Maria Ruiza Yee, Eduardo Espiridon, Adeolu O Oladunjoye, Udema Millsaps, Nailah Harvey, Anish H Vor. The Use of Clozapine in the Serious Mental Illness Patients Enrolled in an Assertive Community Treatment Program. Cureus. vol 13. issue 5. 2021-07-01. PMID:34188983. |
clozapine has shown superior efficacy over first- and most second-generation antipsychotics in both treating treatment-resistant and non-treatment-resistant schizophrenia which has been supported by several large trials. |
2021-07-01 |
2023-08-13 |
Not clear |
| Maria Ruiza Yee, Eduardo Espiridon, Adeolu O Oladunjoye, Udema Millsaps, Nailah Harvey, Anish H Vor. The Use of Clozapine in the Serious Mental Illness Patients Enrolled in an Assertive Community Treatment Program. Cureus. vol 13. issue 5. 2021-07-01. PMID:34188983. |
in fact, clozapine has been approved by the fda for use in refractory schizophrenia and suicidality in schizoaffective disorder. |
2021-07-01 |
2023-08-13 |
Not clear |
| Maria Ruiza Yee, Eduardo Espiridon, Adeolu O Oladunjoye, Udema Millsaps, Nailah Harvey, Anish H Vor. The Use of Clozapine in the Serious Mental Illness Patients Enrolled in an Assertive Community Treatment Program. Cureus. vol 13. issue 5. 2021-07-01. PMID:34188983. |
clozapine remains the gold standard in the treatment of refractory schizophrenia. |
2021-07-01 |
2023-08-13 |
Not clear |
| Sera A J de With, Wai H Man, Coen Maas, Maarten Ten Berg, Wiepke Cahn, Arnold C Koekman, Wouter W van Solinge, Tamar Ta. Neutrophil fluorescence in clozapine users is attributable to a 14kDa secretable protein. Pharmacology research & perspectives. vol 8. issue 5. 2021-06-29. PMID:32812697. |
clozapine is the only antipsychotic agent with demonstrated efficacy in refractory schizophrenia. |
2021-06-29 |
2023-08-13 |
Not clear |
| Jaehyuck P Im, James R Pellegrini, Rezwan Munshi, Leonid Rankov, Amgad N Makaryu. "My Heart Said It's Swollen": A Rare Case of Clozapine-Induced Myocarditis in a Schizophrenic Patient. Cureus. vol 13. issue 5. 2021-06-29. PMID:34178494. |
clozapine is a food and drug administration-approved, second-generation antipsychotic used to treat treatment-resistant schizophrenia. |
2021-06-29 |
2023-08-13 |
Not clear |
| Elias Wagner, William G Honer, Iris E Sommer, Sanne Koops, Daniel M Blumberger, Zafiris J Daskalakis, Jozarni J Dlabac-De Lange, Leonie Bais, Henderikus Knegtering, André Aleman, Tomas Novak, Monika Klirova, Christina Slotema, Jerome Brunelin, Emmanuel Poulet, Milenko Kujovic, Joachim Cordes, Thomas Wobrock, Dan Siskind, Peter Falkai, Thomas Schneider-Axmann, Alkomiet Hasa. Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 22. issue 1. 2021-06-28. PMID:32081071. |
repetitive transcranial magnetic stimulation (rtms) for schizophrenia patients treated with clozapine. |
2021-06-28 |
2023-08-13 |
Not clear |
| Bettina Konte, James T R Walters, Dan Rujescu, Sophie E Legge, Antonio F Pardiñas, Dan Cohen, Munir Pirmohamed, Jari Tiihonen, Annette M Hartmann, Jan P Bogers, Jan van der Weide, Karen van der Weide, Anu Putkonen, Eila Repo-Tiihonen, Tero Hallikainen, Ed Silva, Oddur Ingimarsson, Engilbert Sigurdsson, James L Kennedy, Patrick F Sullivan, Marcella Rietschel, Gerome Breen, Hreinn Stefansson, Kari Stefansson, David A Collier, Michael C O'Donovan, Ina Gieglin. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational psychiatry. vol 11. issue 1. 2021-06-28. PMID:33846298. |
the atypical antipsychotic clozapine is the only effective medication for treatment-resistant schizophrenia. |
2021-06-28 |
2023-08-13 |
Not clear |
| Claudio Ciprian, Kirill Masychev, Maryam Ravan, James P Reilly, Duncan Maccrimmo. A Machine Learning Approach Using Effective Connectivity to Predict Response to Clozapine Treatment. IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society. vol 28. issue 12. 2021-06-24. PMID:33513093. |
clozapine is an anti-psychotic drug that is known to be effective in the treatment of patients with chronic treatment-resistant schizophrenia (trs-scz), commonly estimated to be around one third of all cases. |
2021-06-24 |
2023-08-13 |
Not clear |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. |
2021-06-23 |
2023-08-13 |
human |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
this study investigated subcortical morphometric changes 6 months after switching treatment to clozapine in patients with treatment-resistant schizophrenia compared with healthy volunteers, and the relationships between longitudinal volume changes and clinical variables. |
2021-06-23 |
2023-08-13 |
human |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
in total, 1.5t mri images were acquired at baseline before commencing clozapine and again after 6 months of treatment for 33 patients with treatment-resistant schizophrenia and 31 controls, and processed using the longitudinal pipeline of freesurfer v.5.3.0. |
2021-06-23 |
2023-08-13 |
human |
| Giulia Tronchin, Theophilus N Akudjedu, Mohamed Ahmed, Laurena Holleran, Brian Hallahan, Dara M Cannon, Colm McDonal. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 8. 2021-06-23. PMID:32268345. |
patients with treatment-resistant schizophrenia display progressive subcortical volume deficits after switching to clozapine despite experiencing symptomatic improvement. |
2021-06-23 |
2023-08-13 |
human |
| Kohei Kitagawa, Shusuke Uekusa, Kazuhiro Matsuo, Kei Moriyama, Tatsuro Yamamoto, Yuji Yada, Masafumi Kodama, Yoshiki Kishi, Takashi Yoshi. Risk factors for clozapine-induced central nervous system abnormalities in Japanese patients with treatment-resistant schizophrenia. Asian journal of psychiatry. vol 60. 2021-06-21. PMID:33866283. |
we retrospectively analyzed data from 106 patients with schizophrenia who received clozapine treatment through our hospital. |
2021-06-21 |
2023-08-13 |
Not clear |
| Neslyne B Augustin, Michael Maroule. Hyperleukocytosis during clozapine treatment: A rare presentation of B-cell Acute lymphoblastic leukemia. Leukemia research reports. vol 15. 2021-06-19. PMID:34141565. |
clozapine has been widely used as an antipsychotic drug for the treatment of refractory schizophrenia. |
2021-06-19 |
2023-08-13 |
Not clear |
| Neslyne B Augustin, Michael Maroule. Hyperleukocytosis during clozapine treatment: A rare presentation of B-cell Acute lymphoblastic leukemia. Leukemia research reports. vol 15. 2021-06-19. PMID:34141565. |
we report the case of a 31-year-old patient who developed acute lymphoblastic leukemia shortly after starting treatment with clozapine for refractory schizophrenia. |
2021-06-19 |
2023-08-13 |
Not clear |
| Rocco F Marotta, Frank D Buono, Amir Garakani, Eric Collins, Brianna Cerrito, David Rowe David Row. The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 32. issue 2. 2021-06-18. PMID:32343282. |
the effects of augmenting clozapine with oxytocin in schizophrenia: an initial case series. |
2021-06-18 |
2023-08-13 |
Not clear |
| Nian Liu, Yuan Xiao, Wenjing Zhang, Biqiu Tang, Jiaxin Zeng, Na Hu, Shah Chandan, Qiyong Gong, Su Lu. Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients. Translational psychiatry. vol 10. issue 1. 2021-06-18. PMID:32398765. |
to explore the different patterns of gray matter alterations among chronic never treated patients and those treated with monotherapy, we recruited 35 never-treated chronic schizophrenia patients with illness durations ranging from 5 to 48 years, 20 illness duration-matched risperidone monotherapy and 20 clozapine monotherapy patients, and 55 healthy controls. |
2021-06-18 |
2023-08-13 |
Not clear |
| Robert Løvsletten Smith, Kevin O'Connell, Lavinia Athanasiu, Srdjan Djurovic, Marianne Kristiansen Kringen, Ole A Andreassen, Espen Molde. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. Translational psychiatry. vol 10. issue 1. 2021-06-18. PMID:32555152. |
identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. |
2021-06-18 |
2023-08-13 |
Not clear |